A Phase 3, Multicenter, Randomized, Open-label, Active-Controlled Study of the Safety and Efficacy of Roxadustat in the Treatment of Anemia in Dialysis Patients
Latest Information Update: 10 Feb 2023
At a glance
- Drugs Roxadustat (Primary) ; Epoetin alfa
- Indications Anaemia
- Focus Adverse reactions; Registrational; Therapeutic Use
- Acronyms ROCKIES
- Sponsors AstraZeneca
- 07 Feb 2023 Results of pooled analysis from four studies (n=2142:NCT02021318, NCT02052310, NCT02273726, NCT02174731) assessing the safety of roxadustat in patients with non dialysis dependent or incident dialysis dialysis dependent chronic kidney disease published in the Advances in Therapy
- 09 Nov 2022 Results of systematic review included some of the data from DOLOMITES, HIMALAYAS and ROCKIES for assessing efficacy and safety of hypoxia-inducible factor prolyl hydroxylase inhibitors for treatment of anaemia of chronic kidney disease, presented at the 25th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
- 01 Apr 2022 Results published in the Journal of the American Society of Nephrology